Polypeptide molecule and application thereof
阅读说明：本技术 一种多肽分子及其应用 (Polypeptide molecule and application thereof ) 是由 陈超 林树珊 李玉 李晓平 陈小锋 李文佳 刘亮 付正 于 2020-03-04 设计创作，主要内容包括：本申请提供了一种FGF21多肽,其具有下述性能中的一种或多种：结构稳定,半衰期较长；免疫原性较低；生物活性效力高；可增强降糖活性及降脂活性。本申请还提供了一种融合蛋白或免疫缀合物,其包含本申请所述的FGF21多肽。(The present application provides an FGF21 polypeptide having one or more of the following properties: the structure is stable, and the half-life period is longer; the immunogenicity is low; the biological activity efficacy is high; can enhance the activity of reducing blood sugar and blood fat. The present application also provides a fusion protein or immunoconjugate comprising the FGF21 polypeptide described herein.)
An FGF21 polypeptide comprising amino acid substitutions in the following positions compared to the amino acid sequence as shown in SEQ ID NO. 1: l98, S167, P171, R175 and R19.
2. The FGF21 polypeptide of claim 1, further comprising an amino acid substitution at one or more positions selected from the group consisting of: r135, a180, a31 and G43.
3. The FGF21 polypeptide of any one of claims 1-2, comprising an amino acid substitution at an amino acid residue selected from the group consisting of:
(1) l98, S167, P171, R175, R19 and R135;
(2) l98, S167, P171, R175, R19 and a 180;
(3) l98, S167, P171, R175, R19, a31 and G43; and the number of the first and second groups,
(4) l98, S167, P171, R175, R19, R135, a31 and G43.
4. The FGF21 polypeptide of any one of claims 1-3, wherein the amino acid substitution at L98 is L98R.
5. The FGF21 polypeptide of any one of claims 1-4, wherein the amino acid substitution at S167 is S167H.
6. The FGF21 polypeptide of any one of claims 1-5, wherein the amino acid substitution at P171 is selected from the group consisting of P171A, P171G, and P171N.
7. The FGF21 polypeptide of any one of claims 1-6, wherein the amino acid substitution at R175 is R175L.
8. The FGF21 polypeptide of any one of claims 1-7, wherein the amino acid substitution at R19 is R19V.
9. The FGF21 polypeptide of any one of claims 1-8, further comprising one or more amino acid substitutions selected from the group consisting of: R135V, a180E, a31C and G43C.
10. The FGF21 polypeptide of any one of claims 1-9, comprising an amino acid substitution selected from the group consisting of:
(1) L98R, S167H, P171A, R175L and R19V;
(2) L98R, S167H, P171G, R175L and R19V;
(3) L98R, S167H, P171G, R175L, R19V and R135V;
(4) L98R, S167H, P171G, R175L, R19V and a 180E;
(5) L98R, S167H, P171A, R175L, R19V and R135V;
(6) L98R, S167H, P171A, R175L, R19V, a31C, and G43C;
(7) L98R, S167H, P171G, R175L, R19V, a31C, and G43C;
(8) L98R, S167H, P171G, R175L, R19V, R135V, a31C, and G43C;
(9) L98R, S167H, P171A, R175L, R19V, R135V, a31C, and G43C; and the number of the first and second groups,
(10) L98R, S167H, P171A, R175L, R19V and a 180E.
11. The FGF21 polypeptide of any one of claims 1-10, comprising an amino acid sequence set forth in any one of the following groups: 2-11 of SEQ ID NO.
12. A fusion protein or immunoconjugate comprising the FGF21 polypeptide of any one of claims 1-11.
13. The fusion protein or immunoconjugate of claim 12, further comprising an immunoglobulin Fc domain.
14. The fusion protein or immunoconjugate of claim 13, wherein the immunoglobulin Fc domain is C-terminal to the FGF21 polypeptide.
15. The fusion protein or immunoconjugate of any one of claims 13-14, the immunoglobulin Fc domain is an Fc of a human IgG or a functional variant thereof.
16. The fusion protein or immunoconjugate of any one of claims 13-15, the immunoglobulin Fc domain comprising an amino acid sequence set forth in any one of the following groups: 12-13 of SEQ ID NO.
17. The fusion protein or immunoconjugate of any one of claims 12-16, further comprising a linker.
18. The fusion protein or immunoconjugate of claim 17, wherein the linker is a peptide linker.
19. The fusion protein or immunoconjugate of any one of claims 17-18, wherein the N-terminus of the linker is linked to the C-terminus of the immunoglobulin Fc domain, and the C-terminus of the linker is linked to the N-terminus of the FGF21 polypeptide.
20. The fusion protein or immunoconjugate of any one of claims 17-19, said linker comprising the amino acid sequence set forth in seq id No. 16.
21. The fusion protein or immunoconjugate of any one of claims 12 to 20, comprising an amino acid sequence set forth in any one of the following groups: SEQ ID NO 17-26.
22. The fusion protein or immunoconjugate of claim 12, further comprising GLP-1 or a functional variant thereof.
23. The fusion protein or immunoconjugate of claim 22, wherein the GLP-1 or functional variant thereof comprises an amino acid sequence set forth in any one of the following groups: 14-15 of SEQ ID NO.
24. The fusion protein or immunoconjugate of any one of claims 22-23, further comprising an immunoglobulin Fc domain.
25. The fusion protein or immunoconjugate of claim 24, wherein the immunoglobulin Fc domain is C-terminal to the FGF21 polypeptide.
26. The fusion protein or immunoconjugate of any one of claims 24-25, said immunoglobulin Fc domain is N-terminal to said GLP-1 or variant thereof.
27. The fusion protein or immunoconjugate of any one of claims 24-26, the immunoglobulin Fc domain is an Fc of a human IgG or a functional variant thereof.
28. The fusion protein or immunoconjugate of any one of claims 22-27, the immunoglobulin Fc domain comprising an amino acid sequence set forth in any one of the following groups: 12-13 of SEQ ID NO.
29. The fusion protein or immunoconjugate of any one of claims 22-28, further comprising a linker.
30. The fusion protein or immunoconjugate of claim 29, wherein the linker is a peptide linker.
31. The fusion protein or immunoconjugate of any one of claims 29-30, wherein the linker comprises a first linker connected N-terminal to the C-terminal of the immunoglobulin Fc domain and C-terminal to the N-terminal of the FGF21 polypeptide.
32. The fusion protein or immunoconjugate of any one of claims 29-31, wherein said linker comprises a second linker connected N-terminally to the C-terminus of the GLP-1 or variant thereof and C-terminally to the N-terminus of the immunoglobulin Fc domain.
33. The fusion protein or immunoconjugate of any one of claims 29-32, each of the first linker and the second linker independently comprises an amino acid sequence set forth in SEQ ID No. 16.
34. The fusion protein or immunoconjugate of any one of claims 22 to 33, comprising an amino acid sequence set forth in any one of the following groups: 27-36 of SEQ ID NO.
35. An isolated nucleic acid molecule encoding the FGF21 polypeptide of any one of claims 1-11 and/or the fusion protein or immunoconjugate of any one of claims 12-34.
36. A vector comprising the isolated nucleic acid molecule of claim 35.
37. A cell comprising or expressing the FGF21 polypeptide of any one of claims 1-11, the fusion protein or immunoconjugate of any one of claims 12-34, the isolated nucleic acid molecule of claim 35, or the vector of claim 36.
38. A pharmaceutical composition comprising the FGF21 polypeptide of any one of claims 1-11, the fusion protein or immunoconjugate of any one of claims 12-34, the isolated nucleic acid molecule of claim 35, the vector of claim 32, or the cell of claim 33, and optionally a pharmaceutically acceptable adjuvant.
39. Use of the FGF21 polypeptide of any one of claims 1-11, the fusion protein or immunoconjugate of any one of claims 12-34, for the preparation of a therapeutic medicament for the treatment of a disease caused by a metabolic disorder of FGF 21.
40. The use according to claim 39, wherein the disease caused by a metabolic disorder of FGF21 comprises diabetes, fatty liver, obesity and/or pancreatitis.
Technical Field
The application relates to the field of biomedicine, in particular to a polypeptide molecule and application thereof.
Background
Glucagon-like peptide-1 (GLP-1) is an incretin secreted by L cells of the small intestine, which stimulates the beta cells of the islets of langerhans to secrete insulin, thus maintaining the balance of insulin in the patient. GLP-1 indirectly acts through insulin, only acts on type II diabetes, and limits the application range and effect of the GLP-1; at the same time, GLP-1 has been reported to have a potential thyroid cancer risk.
FGF21 belongs to one of the FGF family (FGFs) members. The FGF21 can promote glucose absorption of adipocytes and enhance insulin sensitivity, and compared with insulin, FGF21 does not cause side effects such as hypoglycemia and the like, can more effectively protect beta islet cells and promote regeneration and repair of the islet beta cells, and does not cause potential tumor risks due to the fact that mitogenic activity is absent. FGF21 holds promise as a drug for the treatment of
However, FGF21 also faces significant challenges in terms of pharmacy. This is due to the short half-life of FGF21, which is only about one hour in a mouse model (Xu et al, 2009). On the other hand, FGF21 also has limited biological activity in vivo. Therefore, modification of FGF21 is highly desirable.
Disclosure of Invention
The present application provides an FGF21 polypeptide having at least one or more of the following characteristics: (1) the structure is stable, and the half-life period is longer; (2) the immunogenicity is low; (3) the biological activity efficacy is high; (4) can enhance the activity of reducing blood sugar and blood fat.
In one aspect, the present application provides a FGF21 polypeptide comprising an amino acid substitution at the following position compared to the amino acid sequence set forth in SEQ ID NO: 1: l98, S167, P171, R175 and R19.
In certain embodiments, the FGF21 polypeptide further comprises an amino acid substitution at one or more positions selected from the group consisting of: r135, a180, a31 and G43.
In certain embodiments, the FGF21 polypeptide comprises an amino acid substitution at an amino acid residue selected from the group consisting of SEQ ID NO: 1: (1) l98, S167, P171, R175 and R19; (2) l98, S167, P171, R175, R19 and R135; (3) l98, S167, P171, R175, R19 and a 180; (4) l98, S167, P171, R175, R19, a31 and G43; and, (5) L98, S167, P171, R175, R19, R135, a31 and G43.
In certain embodiments, the amino acid substitution at L98 is L98R.
In certain embodiments, the amino acid substitution at S167 is S167H.
In certain embodiments, the amino acid substitution at P171 is selected from the group consisting of P171A, P171G, and P171N.
In certain embodiments, the amino acid substitution at R175 is R175L.
In certain embodiments, the amino acid substitution at R19 is R19V.
In certain embodiments, the FGF21 polypeptide further comprises one or more amino acid substitutions selected from the group consisting of: R135V, a180E, a31C and G43C.
In certain embodiments, the FGF21 polypeptide comprises an amino acid substitution selected from the group consisting of SEQ ID NO:1, as compared to the amino acid sequence set forth in SEQ ID NO: (1) L98R, S167H, P171A, R175L and R19V; (2) L98R, S167H, P171G, R175L and R19V; (3) L98R, S167H, P171G, R175L, R19V and R135V; (4) L98R, S167H, P171G, R175L, R19V and a 180E; (5) L98R, S167H, P171A, R175L, R19V and R135V; (6) L98R, S167H, P171A, R175L, R19V, a31C, and G43C; (7) L98R, S167H, P171G, R175L, R19V, a31C, and G43C; (8) L98R, S167H, P171G, R175L, R19V, R135V, a31C, and G43C; (9) L98R, S167H, P171A, R175L, R19V, R135V, a31C, and G43C; and, (10) L98R, S167H, P171A, R175L, R19V and a 180E.
In certain embodiments, the polypeptide comprises an amino acid sequence set forth in any one of the following groups: 2-11 of SEQ ID NO.
In another aspect, the present application provides a fusion protein or immunoconjugate comprising the FGF21 polypeptide described herein.
In certain embodiments, the fusion protein or immunoconjugate further comprises an immunoglobulin Fc domain. In certain embodiments, the immunoglobulin Fc domain is C-terminal to the FGF21 polypeptide. In certain embodiments, the immunoglobulin Fc domain is an Fc of a human IgG or a functional variant thereof. In certain embodiments, the immunoglobulin Fc domain comprises an amino acid sequence set forth in any one of the following groups: 12-13 of SEQ ID NO.
In certain embodiments, the fusion protein further comprises a linker. In certain embodiments, the linker is a peptide linker.
In certain embodiments, the N-terminus of the linker is linked to the C-terminus of the immunoglobulin Fc domain, and the C-terminus of the linker is linked to the N-terminus of the FGF21 polypeptide.
In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO 16.
In certain embodiments, the fusion protein or immunoconjugate comprises an amino acid sequence set forth in any one of the following groups: SEQ ID NO 17-26.
In certain embodiments, the fusion protein or immunoconjugate further comprises GLP-1 or a functional variant thereof. In certain embodiments, the GLP-1 or functional variant thereof comprises an amino acid sequence as set forth in any one of the following groups: SEQ ID NO. 14-15.
In certain embodiments, the fusion protein or immunoconjugate further comprises an immunoglobulin Fc domain. In certain embodiments, the immunoglobulin Fc domain is C-terminal to the FGF21 polypeptide.
In certain embodiments, the immunoglobulin Fc domain is an Fc of a human IgG or a functional variant thereof. The immunoglobulin Fc domain comprises an amino acid sequence set forth in any one of the following groups: 12-13 of SEQ ID NO.
In certain embodiments, the fusion protein or immunoconjugate further comprises a linker. In certain embodiments, the linker is a peptide linker.
In certain embodiments, the linker comprises a first linker, the N-terminus of the first linker is linked to the C-terminus of the Fc, and the C-terminus of the first linker is linked to the N-terminus of the FGF21 polypeptide. In certain embodiments, the linker comprises a second linker, the N-terminus of the second linker is linked to the C-terminus of the GLP-1 or variant thereof, and the C-terminus of the second linker is linked to the N-terminus of the Fc.
In certain embodiments, the first linker and the second linker each independently comprise an amino acid sequence set forth in any one of the following groups: 16 in SEQ ID NO.
In certain embodiments, the fusion protein or immunoconjugate comprises an amino acid sequence set forth in any one of the following groups: 27-36 of SEQ ID NO.
In another aspect, the present application provides an isolated nucleic acid molecule encoding a FGF21 polypeptide described herein and/or a fusion protein or immunoconjugate described herein.
In another aspect, the present application provides a vector comprising an isolated nucleic acid molecule described herein.
In another aspect, the present application provides a cell comprising or expressing a FGF21 polypeptide described herein, a fusion protein or immunoconjugate described herein, an isolated nucleic acid molecule described herein, or a vector described herein.
In another aspect, the present application provides a pharmaceutical composition comprising a FGF21 polypeptide described herein, a fusion protein or immunoconjugate described herein, an isolated nucleic acid molecule described herein, a vector described herein, or a cell described herein, and optionally a pharmaceutically acceptable adjuvant.
In certain embodiments, the FGF21 polypeptide described herein, the fusion protein described herein, or the immunoconjugate described herein is used for the preparation of a medicament for the treatment of a disease caused by a metabolic disorder of FGF 21. In certain embodiments, the use according to the present application, wherein the disease caused by a metabolic disorder of FGF21 comprises diabetes, fatty liver, obesity and/or pancreatitis.
Other aspects and advantages of the present disclosure will be readily apparent to those skilled in the art from the following detailed description. Only exemplary embodiments of the present disclosure have been shown and described in the following detailed description. As those skilled in the art will recognize, the disclosure enables those skilled in the art to make changes to the specific embodiments disclosed without departing from the spirit and scope of the invention as claimed in the present application. Accordingly, the descriptions in the drawings and the specification of the present application are illustrative only and not limiting.
Drawings
The specific features of the invention to which this application relates are set forth in the appended claims. The features and advantages of the invention to which this application relates will be better understood by reference to the exemplary embodiments described in detail below and the accompanying drawings. The brief description of the drawings is as follows:
FIG. 1 shows the SDS-PAGE results of FGF21 polypeptides described herein
FIG. 2 shows a schematic of the structure of a fusion protein described herein.
Fig. 3A-3H show mass spectrometric images of fusion proteins described herein.
FIGS. 4A-4B show the results of SDS-PAGE electrophoretic detection of the fusion proteins described herein.
FIGS. 5A-5B show SDS-PAGE electrophoretic detection of fusion proteins described herein.
FIG. 6 shows a comparison of the effect of the fusion proteins described herein on blood glucose in db/db mice.
FIGS. 7A-7D show mass spectrometric images of fusion proteins described herein.
FIG. 8 shows a comparison of the effect of the fusion proteins described herein on the body weight of db/db mice.
FIG. 9 shows a comparison of the effect of the fusion proteins described herein on blood glucose in db/db mice.
FIG. 10 shows a comparison of the effect of the fusion proteins described herein on the rate of weight gain in db/db mice.
FIG. 11 shows a comparison of the effect of the fusion proteins described herein on food intake in db/db mice.
FIG. 12 shows a comparison of the effect of the fusion proteins described herein on total cholesterol in db/db mice.
FIG. 13 shows a comparison of the effect of the fusion proteins described herein on fasting plasma glucose in db/db mice.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The application provides an FGF21 polypeptide, which has a stable structure and a longer half-life period; the immunogenicity is low; the biological activity efficacy is high; can enhance the activity of reducing blood sugar and blood fat.
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification.
In the present application, the term "FGF 21 polypeptide" generally refers to a protein encoded by Fibroblast growth factor 21(FGF21 gene, Fibroblast growth factor 21). In the present application, the FGF21 polypeptide can be human (Homo sapiens) FGF21, the NCBI of which amino acid sequence is referenced as NP _ 061986.1. The protein encoded by the FGF21 gene is a member of the Fibroblast Growth Factor (FGF) family, one of the members of the endocrine subfamily. FGF21 is the major endogenous agonist of FGF21 receptor, consisting of the
In the present application, when describing the substitution of amino acid residues in a sequence, the expression "XnY" generally denotes the substitution of residue X with residue Y at position n in the sequence. For example, an amino acid substitution "R175L" indicates that residue R at position 175 in the sequence is substituted with residue L. In the present application, the term "R19" generally refers to amino acid residue R at position 19 of the amino acid sequence of native FGF 21. In the present application, the native FGF21 is human wild-type FGF21, the NCBI reference sequence of the amino acid sequence of which is NP _ 061986.1; the mature FGF21 sequence lacks the leader sequence compared to the FGF21 wild-type, which contains 181 amino acids. In the present application, the term "native FGF21 sequence" generally refers to the mature human FGF21 sequence, the amino acid sequence of which can be represented as SEQ ID No. 1.
In this application, the term "immunoglobulin Fc domain" generally refers to a domain that comprises portions of the CH2 and CH3 constant regions of an immunoglobulin (e.g., an antibody). For example, the immunoglobulin Fc domain may be a domain consisting of the hinge region, CH2, and CH3 constant region portions of an immunoglobulin (e.g., an antibody). For example, the immunoglobulin may be a human immunoglobulin. For example, the immunoglobulin may be
In the present application, the term "functional variant" generally refers to a protein or polypeptide in which one or more amino acids have been substituted, deleted or added based on the amino acid sequence of the protein of interest (e.g., the FGF21 polypeptide, the fusion protein or immunoconjugate, the immunoglobulin Fc domain, or the GLP-1), while still retaining at least one of the biological properties of the protein of interest. In the present application, "plurality" of the "one or more" amino acid substitutions generally refers to substitutions of greater than 1 amino acid. For example, 1 to 30, 1 to 20, 1 to 10, 1 to 5, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. For example, the functional variant may comprise a protein or polypeptide that has been altered by at least 1, such as 1-30, 1-20 or 1-10, and further such as 1, 2, 3, 4 or 5 amino acid substitutions, deletions and/or insertions. The functional variant may substantially retain the biological properties of the protein or the polypeptide prior to the alteration (e.g., substitution, deletion, or addition). For example, the functional variant may retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity of the protein or the polypeptide prior to the alteration. For example, the substitution may be a conservative substitution.
In the present application, the functional variant may also be a homologue of the protein of interest (e.g., the FGF21 polypeptide, the fusion protein or immunoconjugate, the immunoglobulin Fc domain, or the GLP-1). In the present application, the homolog may be, for example, a protein or polypeptide having at least about 85% (e.g., having at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) sequence homology to the amino acid sequence of the protein of interest.
In the present application, homology generally refers to similarity, similarity or relatedness between two or more sequences. The "percentage of sequence homology" can be calculated by: the two sequences to be aligned are compared in a comparison window, the number of positions in the two sequences at which the same nucleobase (e.g., A, T, C, G, I) or the same amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, gin, Cys, and Met) is determined to yield the number of matched positions, the number of matched positions is divided by the total number of positions in the comparison window (i.e., the window size), and the result is multiplied by 100 to yield the percentage of sequence homology. Alignment to determine percent sequence homology can be accomplished in a variety of ways known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. One skilled in the art can determine suitable parameters for aligning sequences, including any algorithms necessary to achieve maximum alignment over the full length of the sequences being compared or over a region of the target sequence. The homology can also be determined by the following method: FASTA and BLAST. The FASTA algorithm is described in "improved tools for biological sequence comparison" by w.r.pearson and d.j.lipman, proceedings of the national academy of sciences of the united states (proc.natl.acad.sci.), 85: 2444 2448, 1988; and "rapid and sensitive protein similarity search" by d.j.lipman and w.r.pearson, Science, 227: 1435-1441, 1989. BLAST algorithms are described in "a basic local contrast (alignment) search tool" by s.altschul, w.gish, w.miller, e.w.myers and d.lipman, journal of molecular biology, 215: 403-410, 1990.
In the present application, the term "fusion protein" generally refers to a protein resulting from the fusion of two or more proteins or polypeptides. In the present application, the fusion protein may comprise the FGF21 polypeptide. Genes or nucleic acid molecules encoding the two or more proteins or polypeptides may be linked to each other to form a fusion gene or a fused nucleic acid molecule, which may encode the fusion protein. The fusion protein can be artificially created by recombinant DNA technology for biological research or therapy. In the present application, the fusion protein may further comprise a domain other than the FGF21 polypeptide. In the present application, the fusion protein may further comprise a linker, and/or other domains, linking the FGF21 polypeptide and the domain other than the FGF21 polypeptide.
In the present application, the term "linker" generally refers to a functional structure that can link two or more polypeptides by peptide bonds. In this application, the terms "linker" and "linker" are used interchangeably. When forming the fusion protein of the present application, a linker may be used. Linkers may be composed of amino acids linked together by peptide bonds. The linker of the present application may be any length or composition of linkers. In certain embodiments, a linker may be composed of 1-20 amino acids linked by peptide bonds. For example, the amino acids may be selected from the 20 naturally occurring amino acids. In certain embodiments, the amino acid may be selected from the group consisting of glycine, serine, alanine, proline, asparagine, glutamine, and lysine. In certain embodiments, the linker is composed of multiple amino acids that are sterically unhindered. For example, the sterically unhindered amino acids may be glycine and alanine. The linker may be a G-rich polypeptide, for example, it may be selected from (G)3-S (i.e., "GGGS"), (G)4-S (i.e., "GGGGS"), and (G)5-S (i.e., "GGGGGS"). In some embodiments, the linker may comprise GGGGSGGGGS, GGGGSGGGGSGGGGS or GGGGSGGGGSGGGGSA. Other suitable linkers may include: GGGGGSGGGSGGGGS, GGGKGGGG, GGGNGSGG, GGGCGGGG and GPNGG, etc. The linkers described herein can also be non-peptide linkers. For example, an alkyl linker, such as-NH- (CH)2)S-c (o) -, wherein s is 2-20. These alkyl linkers may be further substituted with any non-sterically hindered group which may include, but is not limited to, lower alkyl (e.g., C1-C6), lower acyl, halogen (e.g., Cl, Br), CN, NH2Or a phenyl group. Exemplary non-peptide linkers can also be polyethylene glycol linkers, wherein the linker can have a molecular weight of 100-.
In the present application, the term "immunoconjugate" generally refers to a conjugate comprising the FGF21 polypeptide, and other components conjugated to the FGF21 polypeptide. The immunoconjugate may be a recombinant polypeptide. In the present application, the component conjugated to the FGF21 polypeptide may include cytotoxins, chemotherapeutic drugs, immunosuppressive agents, and/or radioisotopes, among others. For example, examples of suitable cytotoxic and chemotherapeutic agents for forming the conjugates can be found in W005/103081. In the present application, the immunoconjugate may further comprise a linker, and/or other domain, linking the FGF21 polypeptide and the component conjugated to the FGF21 polypeptide.
In this application, the term "GLP-1" generally refers to a peptide secreted by the endocrine cells of the ileum. In the present application, the GLP-1 may be human GLP-1. The amino acid sequence of human GLP-1 is UniProtKB/Swiss-Prot accession number P0C6A0.1. The GLP-1 can be used as a target point of the action of the medicament for treating
In the present application, the term "nucleic acid molecule" generally refers to an isolated form of nucleotides, deoxyribonucleotides or ribonucleotides or analogs thereof of any length, isolated from their natural environment or artificially synthesized. The nucleic acid molecules described herein can be isolated. For example, it may be produced or synthesized by: (i) in vitro amplified, e.g., by Polymerase Chain Reaction (PCR), (ii) recombinantly produced by cloning, (iii) purified, e.g., by enzymatic cleavage and gel electrophoresis fractionation, or (iv) synthesized, e.g., by chemical synthesis. In certain embodiments, the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA techniques. In the present application, nucleic acids encoding the antibodies or antigen-binding fragments thereof can be prepared by a variety of methods known in the art, including, but not limited to, overlap extension PCR using restriction fragment procedures or using synthetic oligonucleotides, as described in Sambrook et al, molecular cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausube et al Current Protocols in Molecular Biology, Greene publishing and Wiley-Interscience, New York N.Y., 1993.
In the present application, the term "cell" generally refers to an individual cell, cell line or cell culture that may or may already contain an immunoconjugate described herein, may or may already contain a plasmid or vector comprising a nucleic acid molecule described herein, or is capable of expressing an antibody or antigen-binding fragment thereof described herein. The cell may be a prokaryotic cell (e.g., E.coli) or a eukaryotic cell (e.g., a yeast cell, such as a COS cell, a Chinese Hamster Ovary (CHO) cell, a HeLa cell, a HEK293 cell, a COS-1 cell, an NS0 cell, or a myeloma cell). In certain embodiments, the cell is a mammalian cell. For example, the mammalian cell can be a HEK293 cell. In the present application, the term "pharmaceutical composition" is generally meant to include the active ingredient in combination with an inert or active carrier, thereby rendering the composition suitable for diagnostic or therapeutic use in vivo or in vitro or ex vivo.
In the present application, the term "diseases caused by metabolic disorders" generally refers to diseases caused by the accumulation or deficiency of certain metabolic substances (e.g., sugars, lipids, proteins, purines, etc.) due to the occurrence of disorders in biochemical processes in vivo. The diseases caused by metabolic disorders described herein may be caused by innate factors or by acquired factors. The innate factors may include congenital genetic defects, such as mucolipidosis. The acquired factors may include pathological changes and dysfunction of the internal organs, such as renal failure, nephrotic syndrome, etc.; can also comprise external factors including medicines and foods, such as blood 25-hydroxyvitamin D reduction caused by long-term taking of antiepileptic drugs, followed by calcium and phosphorus reduction in blood and alkaline phosphatase increase; hyperlipoproteinemia, arteriosclerosis and cholelithiasis caused by eating foods containing excessive fat and/or cholesterol. In the present application, the diseases caused by the metabolic disorders may include diabetes, fatty liver, obesity, and pancreatitis.
In the present application, the term "pharmaceutically acceptable adjuvant" refers to a pharmaceutically acceptable formulation carrier, solution or additive that enhances the properties of the formulation. Such additives are well known to those skilled in the art. Although any pharmaceutically acceptable diluent is suitable, it is particularly preferred that the excipient for parenteral administration is a saline solution. For example, sodium chloride, mannitol, and the like. In the present application, the term "IgG constant region domain" generally refers to a polypeptide domain or polypeptide fragment that includes an antibody heavy chain constant region, a hinge region, and an antibody light chain constant region. The antibody may be an IgG antibody, for example, an antibody of the IgG1, IgG2, IgG3 or IgG4 subtype. In the present application, the term "fragment" of an IgG constant region domain generally refers to a portion of an IgG constant region domain, but still retains at least a portion of its activity. For example, the fragment may include one or more domains or fragments of CL, CH1, hinge region, CH2, and
In this application, the terms "first" and "second" are used for descriptive purposes only and have no other meaning. For example, the first linker, the second linker.
In the present application, the term "comprising" is generally intended to include the explicitly specified features, but not to exclude other elements.
In the present application, the terms "protein" and "polypeptide" are used interchangeably and, in their broadest sense, refer to a compound consisting of two or more amino acids, amino acid analogs, or peptidomimetic subunits. The two or more subunits may be linked by a peptide bond. In certain embodiments, the two or more subunits may be linked by other bonds, such as ester bonds, ether bonds, amino groups, and the like. A protein or polypeptide must contain at least two amino acids and there is no limit to the maximum number of amino acids that can make up a protein or peptide sequence. In this application, the term "amino acid" generally refers to natural and/or unnatural or synthetic amino acids, including D and L optical isomers of amino acids (e.g., glycine and its D and L optical isomers), amino acid analogs, peptidomimetics, and the like.
In the present application, the terms "homology", "identity" or "similarity" are used interchangeably and generally refer to sequence similarity between two peptides or proteins or between two nucleic acid molecules. Homology can be determined by comparing the positions in the sequences that can be aligned for comparison purposes. In the molecules being compared, when a position in their sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. The degree of homology between sequences varies with the number of matching or homologous positions shared by the sequences. "unrelated" or "non-homologous" sequences means that the sequences being compared share less than 40% identity, or less than 25% identity.
In the present application, the term "at least 80% sequence identity" when referring to amino acid sequence identity of a polypeptide generally refers to at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the respective reference sequence.
In this application, the term "about" when used in connection with a numerical value generally includes values within the following ranges: this range has a lower limit that is 5% less than the stated value and has an upper limit that is 5% greater than the stated value.
In the present application, the term "composition" is generally a combination of two or more substances, for example, an active agent in combination with other inert or active compounds.
In the present application, the term "therapeutically effective amount" generally refers to the minimum dose of active ingredient required to produce a therapeutic benefit to a subject. For example, a "therapeutically effective amount" for a patient exhibiting or susceptible to type 2 diabetes, obesity, or metabolic syndrome, or for preventing the onset thereof, refers to an amount that induces, ameliorates, or causes an improvement in the pathological symptoms, disease progression, or physiological condition associated with or countered by the above-described disorder.
In the present application, the term "subject" or "patient" may be a human, but may also be a non-human animal, more specifically a companion animal (e.g., dog, cat, etc.), a farm animal (e.g., cow, sheep, pig, horse, etc.), or a laboratory animal (e.g., rat, mouse, guinea pig, etc.), and the like.
FGF21 Polypeptides
In one aspect, the FGF21 polypeptide comprising an amino acid substitution at a position as compared to the amino acid sequence set forth in SEQ ID NO: 1: l98, S167, P171, R175 and R19. In this application, L98, S167, P171 and R175 refer to respectively residue L at position 98, residue S at position 167, residue P at position 171 and residue R at position 175 of the amino acid sequence shown in SEQ ID NO. 1.
In the present application, the FGF21 polypeptide may further comprise an amino acid substitution at one or more positions selected from the group consisting of: r135, a180, a31 and G43. In this application, R135, A180, A31 and G43 may refer to residue R at position 135, residue A at position 180, residue A at position 31 and residue G at position 43, respectively, of the amino acid sequence shown in SEQ ID NO. 1.
In the present application, the FGF21 polypeptide may comprise an amino acid substitution at an amino acid residue selected from the group consisting of: (1) l98, S167, P171, R175 and R19; (2) l98, S167, P171, R175, R19 and R135; (3) l98, S167, P171, R175, R19 and a 180; (4) l98, S167, P171, R175, R19 and Q173; (5) l98, S167, P171, R175, R19, a31 and G43; (6) l98, S167, P171, R175, R19, R135 and Q173; and, (7) L98, S167, P171, R175, R19, R135, a31 and G43.
In the present application, the amino acid substitution at L98 of the FGF21 polypeptide can be L98R.
In the present application, the amino acid substitution at S167 of the FGF21 polypeptide can be S167H.
In the present application, the amino acid substitution at P171 of the FGF21 polypeptide can be selected from the group consisting of P171A, P171G, and P171N.
In the present application, the amino acid substitution at R175 of the FGF21 polypeptide can be R175L.
In the present application, the amino acid substitution at R19 of the FGF21 polypeptide can be R19V.
In the present application, the FGF21 polypeptide can further comprise one or more amino acid substitutions selected from the group consisting of: R135V, a180E, a31C and G43C. In this application, R135V, A180E, A31C and G43C may respectively indicate that the residue R at position 135 of the amino acid sequence shown in SEQ ID NO. 1 may be substituted by a residue V, the residue A at position 180 may be substituted by a residue E, the residue A at position 31 may be substituted by a residue C, and the residue G at position 43 may be substituted by a residue C.
In the present application, the FGF21 polypeptide may comprise amino acid substitutions selected from the group consisting of SEQ ID NO: 1: (1) L98R, S167H, P171A, R175L and R19V; (2) L98R, S167H, P171G, R175L and R19V; (3) L98R, S167H, P171G, R175L, R19V and R135V; (4) L98R, S167H, P171G, R175L, R19V and a 180E; (5) L98R, S167H, P171A, R175L, R19V and R135V; (6) L98R, S167H, P171A, R175L, R19V, a31C, and G43C; (7) L98R, S167H, P171G, R175L, R19V, a31C, and G43C; (8) L98R, S167H, P171G, R175L, R19V, R135V, a31C, and G43C; (9) L98R, S167H, P171A, R175L, R19V, R135V, a31C, and G43C; and, (10) L98R, S167H, P171A, R175L, R19V and a 180E.
In the present application, the FGF21 polypeptide can comprise an amino acid sequence set forth in any one of the following groups: 2-11 of SEQ ID NO.
For example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171A, R175L, and R19V, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171A, R175L, and R19V can be FGF21-1, the sequence of which can be shown in SEQ ID NO. 2.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171G, R175L, and R19V, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171G, R175L, and R19V can be FGF21-2, the sequence of which can be shown in SEQ ID NO. 3.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171G, R175L, R19V, and R135V, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171G, R175L, R19V and R135V can be FGF21-3, the sequence of which can be set forth in SEQ ID NO. 4.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171G, R175L, R19V, and A180E, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171G, R175L, R19V and A180E can be FGF21-4, the sequence of which can be set forth in SEQ ID NO. 5.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171N, R175L, R19V, and Q173T, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171N, R175L, R19V, and Q173T can be FGF 21-5.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171A, R175L, R19V, and R135V, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171A, R175L, R19V and R135V can be FGF21-6, the sequence of which can be set forth in SEQ ID NO. 6.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171A, R175L, R19V, A31C, and G43C as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions L98R, S167H, P171A, R175L, R19V, a31C, and G43C can be FGF21-7, the sequence of which can be set forth in SEQ ID No. 7.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, L98R, S167H, P171N, R175L, R19V, R135V, and Q173T, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions L98R, S167H, P171N, R175L, R19V, R135V, and Q173T can be FGF 21-8.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171G, R175L, R19V, A31C, and G43C as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171G, R175L, R19V, A31C, and G43C can be FGF21-9, the sequence of which can be set forth in SEQ ID NO. 8.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171G, R175L, R19V, R135V, A31C, and G43C, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171G, R175L, R19V, R135V, A31C, and G43C can be FGF21-10, the sequence of which can be set forth in SEQ ID NO. 9.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171A, R175L, R19V, R135V, A31C, and G43C, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171A, R175L, R19V, R135V, A31C, and G43C can be FGF21-11, the sequence of which can be set forth in SEQ ID NO. 10.
As another example, an FGF21 polypeptide described herein can comprise amino acid substitutions of L98R, S167H, P171A, R175L, R19V, and A180E, as compared to the amino acid sequence set forth in SEQ ID NO. 1. For example, the polypeptide comprising amino acid substitutions of L98R, S167H, P171A, R175L, R19V and A180E can be FGF21-12, the sequence of which can be set forth in SEQ ID NO. 11.
Fusion proteins or immunoconjugates
In another aspect, the present application provides a fusion protein or immunoconjugate comprising the FGF21 polypeptide described herein.
a.Fc
In the present application, the fusion protein or immunoconjugate may further comprise an immunoglobulin Fc domain. In the present application, the immunoglobulin Fc domain may be located C-terminal to the FGF21 polypeptide.
In the fusion proteins or immunoconjugates described herein, the immunoglobulin Fc domain can be the Fc of a human IgG or a functional variant thereof. For example, the immunoglobulin Fc domain may comprise an amino acid sequence set forth in any one of the following groups: 12-13 of SEQ ID NO.
For example, the immunoglobulin Fc domain described herein can be the Fc of human IgG (see UniProt KB or the protein with accession number P01861.1 in Swiss-Prot). The Fc of the human IgG can comprise the amino acid sequence shown in SEQ ID NO. 12.
In the present application, the immunoglobulin Fc domain may also be a functional variant of the Fc of human IgG. For example, the functional variant of the Fc of human IgG may be a polypeptide or protein modified at a specific amino acid residue with a naturally or non-naturally occurring amino acid on the basis of the amino acid sequence of the Fc of
For example, the functional variant of the immunoglobulin Fc domain can be IgG-Fc-PAAK, which can comprise the amino acid sequence shown in
b. Connector
In the present application, the fusion protein may further comprise a linker. In the present application, the linker may be a peptide linker. In the present application, the N-terminus of the linker may be linked to the C-terminus of the immunoglobulin Fc domain, and the C-terminus of the linker may be linked to the N-terminus of the FGF21 polypeptide. In the present application, the linker may comprise the amino acid sequence shown in SEQ ID NO 16.
In the present application, the linker may comprise a first linker and a second linker. For example, the N-terminus of the first linker may be linked to the C-terminus of the immunoglobulin Fc domain, and the C-terminus of the first linker may be linked to the N-terminus of the FGF21 polypeptide. For another example, the N-terminus of the second linker may be linked to the C-terminus of the GLP-1 or variant thereof, and the C-terminus of the second linker may be linked to the N-terminus of the immunoglobulin Fc domain. In the present application, the first linker and/or the second linker may comprise the amino acid sequence shown in SEQ ID NO 16.
c.GLP-1
In the present application, the fusion protein may further comprise GLP-1 or a functional variant thereof. In the present application, said GLP-1 or functional variant thereof may comprise an amino acid sequence as depicted in any one of the following groups: 14-15 of SEQ ID NO.
In the present application, said GLP-1 or functional variant thereof may be human GLP-1 (which is accession number P0C6A0.1 in UniProt KB or Swiss-Prot). The GLP-1 can also be a functional variant of human GLP-1.
For example, the functional variant of human GLP-1 can be GLP-1-GEG, which can comprise the amino acid sequence shown in SEQ ID NO. 15. For example, the GLP-1-GEG can include mutations in A8G, G22E, and R36G. For example, in comparison with the amino acid sequence shown in SEQ ID NO. 14, residue A at
d. Fusion proteins
Single target fusion proteins
In the present application, the fusion protein may be a single-target fusion protein (which may be referred to simply as "single-target" in the present application), i.e., the fusion protein may comprise the FGF21 polypeptide.
In the present application, the single target fusion protein or immunoconjugate may further comprise an immunoglobulin Fc domain. In the present application, the immunoglobulin Fc domain may be located C-terminal to the FGF21 polypeptide. In the present application, the immunoglobulin Fc domain may be the Fc of human IgG or a functional variant thereof. In the present application, the immunoglobulin Fc domain may comprise an amino acid sequence set forth in any one of the following groups: 12-13 of SEQ ID NO.
In the present application, the single target fusion protein or immunoconjugate may further comprise a linker. In the present application, the linker may be a peptide linker. In the present application, the N-terminus of the linker may be linked to the C-terminus of the immunoglobulin Fc domain, and the C-terminus of the linker may be linked to the N-terminus of the FGF21 polypeptide. In the present application, the linker may comprise the amino acid sequence shown in SEQ ID NO 16.
In the present application, the single-target fusion protein or immunoconjugate may comprise an amino acid sequence set forth in any one of the following groups: SEQ ID NO 17-26.
In the present application, the single-target fusion protein may be, from N-terminus to C-terminus, an FGF21 polypeptide, a linker, and an immunoglobulin Fc domain, respectively.
For example, a single-target fusion protein described herein can be a single-target # 1 (which can comprise the amino acid sequence shown in SEQ ID NO: 17), which can comprise the FGF21 polypeptide FGF 21-1.
For example, a single-target fusion protein described herein can be a single-target # 2 (which can comprise the amino acid sequence set forth in SEQ ID NO: 18), which can comprise the FGF21 polypeptide FGF 21-2.
For example, a single-target fusion protein described herein can be a single-target # 3 (which can comprise the amino acid sequence shown in SEQ ID NO: 19), which can comprise the FGF21 polypeptide FGF 21-3.
For example, a single-target fusion protein described herein can be a single-target # 4 (which can comprise the amino acid sequence shown in SEQ ID NO: 20), which can comprise the FGF21 polypeptide FGF 21-4.
For example, a single-target fusion protein described herein can be a single-
For example, a single-target fusion protein described herein can be a single-target # 6 (which can comprise the amino acid sequence shown in SEQ ID NO: 21), which can comprise the FGF21 polypeptide FGF 21-6.
For example, a single-target fusion protein described herein can be a single-target # 7 (which can comprise the amino acid sequence shown in SEQ ID NO: 22), which can comprise the FGF21 polypeptide FGF 21-7.
For example, a single-target fusion protein described herein can be a single-
For example, a single-target fusion protein described herein can be a single-
For example, a single-target fusion protein described herein can be a single-target # 10 (which can comprise the amino acid sequence shown in SEQ ID NO: 24), which can comprise the FGF21 polypeptide FGF 21-10.
For example, a single-target fusion protein described herein can be a single-target # 11 (which can comprise the amino acid sequence shown in SEQ ID NO: 25), which can comprise the FGF21 polypeptide FGF 21-11.
For example, a single-target fusion protein described herein can be a single-target # 12 (which can comprise the amino acid sequence shown in SEQ ID NO: 26), which can comprise the FGF21 polypeptide FGF 21-12.
In the present application, the single target fusion protein may also comprise other modifications. For example, the modifications may include substitutions, additions or deletions of one or more amino acids, so long as the single target fusion protein still comprises FGF21 or a variant thereof of the present application.
For example, the modified single-target fusion protein can be a single-target RGHLQQ (which can comprise the amino acid sequence shown in SEQ ID NO: 45), a single-target RAHL (which can comprise the amino acid sequence shown in SEQ ID NO: 46), a single-target RGHL (which can comprise the amino acid sequence shown in SEQ ID NO: 47), or a single-target RGE (which can comprise the amino acid sequence shown in SEQ ID NO: 48).
Dual target fusion proteins
In the present application, the fusion protein may also be a dual-target fusion protein (which may be referred to simply as "dual-target" in the present application), i.e. the fusion protein may comprise at least two more domains, e.g. it comprises the FGF21 polypeptide and may further comprise GLP-1 or a functional variant thereof. In the present application, the dual-target fusion protein may further comprise an immunoglobulin Fc domain or a functional variant thereof.
In the present application, the dual-target fusion protein may further comprise a linker. In the present application, the linker may be a peptide linker. In the present application, the linker may comprise a first linker and a second linker. For example, the N-terminus of the first linker may be linked to the C-terminus of the immunoglobulin Fc domain, and the C-terminus of the first linker may be linked to the N-terminus of the FGF21 polypeptide. For another example, the N-terminus of the second linker may be linked to the C-terminus of the GLP-1 or variant thereof, and the C-terminus of the second linker may be linked to the N-terminus of the immunoglobulin Fc domain. In the present application, the first linker and/or the second linker may comprise the amino acid sequence shown in SEQ ID NO 16.
In the present application, said dual-target fusion protein may be said FGF21 polypeptide, said first linker, said immunoglobulin Fc domain, said second linker, and said GLP-1, or functional variants thereof, respectively, from N-terminus to C-terminus. Wherein the FGF21 polypeptide comprises an amino acid sequence SEQ ID NO 2-11 or FGF 21-1-FGF 21-12 selected from any one of the following groups; the immunoglobulin Fc domain may comprise an amino acid sequence selected from the group consisting of SEQ id nos 12-13; the GLP-1 or functional variant thereof can comprise an amino acid sequence SEQ ID NO. 14-15; the first linker and/or the second linker may comprise the amino acid sequence shown in SEQ ID NO 16.
For example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
As another example, the dual-target fusion protein described herein can be a dual-
In the present application, the dual-target fusion protein may also be a dual-target RAHL, which may comprise the amino acid sequence shown in SEQ ID NO: 41; the dual-target fusion proteins described herein can also be dual-target RGHL, which can comprise the amino acid sequence set forth in SEQ ID NO: 42; the dual-target fusion proteins described herein can also be dual-target RGHLQQ, which can comprise the amino acid sequence shown in SEQ ID NO. 43; the dual target fusion protein described herein can also be a dual target RAHLQQ, which can comprise the amino acid sequence shown in SEQ ID NO: 44.
In the present application, the protein of interest (e.g., the FGF21 polypeptide, the fusion protein or immunoconjugate, the immunoglobulin Fc domain, or the GLP-1) may each comprise a functional variant and/or a homologue thereof.
Nucleic acid molecules, vectors, cells, pharmaceutical compositions
In another aspect, the present application provides an isolated nucleic acid molecule that encodes an FGF21 polypeptide described herein and/or a fusion protein or immunoconjugate described herein. For example, it may be produced or synthesized by: (i) in vitro amplified, e.g., by Polymerase Chain Reaction (PCR), (ii) recombinantly produced by cloning, (iii) purified, e.g., by enzymatic cleavage and gel electrophoresis fractionation, or (iv) synthesized, e.g., by chemical synthesis. In the present application, the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA techniques.
In another aspect, the present application provides a vector, which can comprise an isolated nucleic acid molecule described herein. In addition, other genes may be included in the vector, such as marker genes that allow selection of the vector in an appropriate host cell and under appropriate conditions. In addition, the vector may contain expression control elements that allow for the proper expression of the coding region in an appropriate host. Such control elements are well known to those skilled in the art and may include, for example, promoters, ribosome binding sites, enhancers and other control elements that regulate gene transcription or mRNA translation, among others. In the present application, the expression control sequences are elements that are adjustable. The specific structure of the expression control sequence may vary depending on the function of the species or cell type, but typically comprises 5 ' non-transcribed sequences and 5 ' and 3 ' non-translated sequences, such as TATA box, capping sequences, CAAT sequences, etc., which are involved in initiation of transcription and translation, respectively. For example, the 5' non-transcriptional expression control sequence may comprise a promoter region that may comprise a promoter sequence for a transcriptional control functional linkage nucleic acid. One or more of the nucleic acid molecules described herein can be operably linked to the expression control element. The vector may include, for example, a plasmid, cosmid, virus, phage, or other vector commonly used in, for example, genetic engineering. For example, the vector is an expression vector.
In another aspect, the present application provides a cell that can comprise or express a FGF21 polypeptide described herein, a fusion protein or immunoconjugate described herein, an isolated nucleic acid molecule described herein, or a vector described herein. Comprising said fusion protein, said immunoconjugate, said nucleic acid molecule, or said vector. In the present application, each or every cell may comprise one or one of the vectors described herein. In the present application, each or every cell may comprise a plurality (e.g., 2 or more) or a plurality (e.g., 2 or more) of the vectors described herein. For example, a vector described herein can be introduced into the cell, e.g., a eukaryotic cell (e.g., a mammalian cell). For example, the mammalian cell can be a HEK293 cell. The vectors described herein can be introduced into the cells by methods known in the art, such as electroporation, lipofectine transfection, lipofectamine transfection, and the like.
Pharmaceutical composition and pharmaceutical application
In another aspect, the present application provides a pharmaceutical composition comprising a FGF21 polypeptide described herein, a fusion protein or immunoconjugate described herein, an isolated nucleic acid molecule described herein, a vector described herein, or a cell described herein, and optionally a pharmaceutically acceptable adjuvant.
The pharmaceutically acceptable adjuvants may include buffers, antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers, amino acids, sugars, chelating agents, counter ions, metal complexes, and/or non-ionic surfactants, and the like.
In the present application, the pharmaceutical composition may be formulated for oral administration, intravenous administration, intramuscular administration, in situ administration at the tumor site, inhalation, rectal administration, vaginal administration, transdermal administration or administration via subcutaneous depot.
In another aspect, the present application provides the use of an FGF21 polypeptide described herein, a fusion protein described herein, or an immunoconjugate described herein, for the preparation of a therapeutic agent useful for the treatment of a disease caused by a metabolic disorder of FGF 21.
For example, the pharmaceutical compositions of the present application may inhibit or delay the development or progression of a disease, and/or may alleviate and/or stabilize a disease state.
The pharmaceutical composition described herein may comprise a therapeutically effective amount of the FGF21 polypeptide, fusion protein, or immunoconjugate. The therapeutically effective amount is the dose required to be able to prevent and/or treat (at least partially treat) a disorder or condition (e.g. a disease caused by a metabolic disorder of FGF21) and/or any complication thereof in a subject suffering from or at risk of developing the same.
In another aspect, the present application provides a method of treating a disease caused by a metabolic disorder of FGF21, comprising administering to a subject an FGF21 polypeptide described herein, a fusion protein described herein, or an immunoconjugate described herein.
In another aspect, the present application provides the FGF21 polypeptide, the fusion protein, or the immunoconjugate described herein for treating a disease caused by a metabolic disorder of FGF 21.
In the present application, the disease caused by the metabolic disorder of FGF21 may include diabetes, fatty liver, obesity, and/or pancreatitis.
Without wishing to be bound by any theory, the following examples are intended only to illustrate the working of the chimeric antigen receptors, vectors, cells, compositions of the present application and are not intended to limit the scope of the invention of the present application.
- 上一篇：一种医用注射器针头装配设备
- 下一篇：一种识别AFP抗原的高亲和力TCR